Livforsakringsbolaget Skandia Omsesidigt Acquires 322 Shares of Stryker Co. (NYSE:SYK)

Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Stryker Co. (NYSE:SYK) by 3.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 10,979 shares of the medical technology company’s stock after purchasing an additional 322 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Stryker were worth $3,295,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of SYK. Norges Bank bought a new stake in shares of Stryker during the 4th quarter valued at about $776,333,000. Moneta Group Investment Advisors LLC lifted its position in Stryker by 109,726.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 3,139,948 shares of the medical technology company’s stock worth $767,686,000 after buying an additional 3,137,089 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its position in Stryker by 87,902.2% in the 1st quarter. Ontario Teachers Pension Plan Board now owns 2,077,732 shares of the medical technology company’s stock worth $555,482,000 after buying an additional 2,075,371 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in Stryker in the 4th quarter worth approximately $312,539,000. Finally, Morgan Stanley increased its stake in Stryker by 21.7% in the 4th quarter. Morgan Stanley now owns 5,978,782 shares of the medical technology company’s stock worth $1,461,753,000 after purchasing an additional 1,066,751 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.5 %

Stryker stock traded down $1.63 during mid-day trading on Wednesday, hitting $336.03. The company had a trading volume of 1,056,153 shares, compared to its average volume of 1,252,351. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average price is $350.70 and its two-hundred day moving average price is $311.86. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The company has a market capitalization of $127.85 billion, a PE ratio of 40.93, a price-to-earnings-growth ratio of 2.73 and a beta of 0.89.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the company posted $3.00 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s payout ratio is currently 38.79%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SYK. Roth Mkm boosted their target price on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Wells Fargo & Company boosted their target price on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. TD Cowen lifted their price target on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target on the stock in a research report on Wednesday, January 31st. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $339.22.

Insider Activity

In related news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders have sold a total of 212,109 shares of company stock valued at $72,845,768 over the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.